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The chronic inﬂammatory bowel diseases (IBDs)—Crohn disease (CD) and ulcerative colitis (UC)—are idiopathic,
inﬂammatory disorders of the gastrointestinal tract. These conditions have a peak incidence in early adulthood
and a combined prevalence of ∼100–200/100,000. Although the etiology of IBD is multifactorial, a signiﬁcant
genetic contribution to disease susceptibility is implied by epidemiological data revealing a sibling risk of ∼35-fold
for CD and ∼15-fold for UC. To elucidate the genetic basis for these disorders, we undertook a genomewide scan
in 158 Canadian sib-pair families and identiﬁed three regions of suggestive linkage (3p, 5q31-33, and 6p) and one
region of signiﬁcant linkage to 19p13 (LOD score 4.6). Higher-density mapping in the 5q31-q33 region revealed
a locus of genomewide signiﬁcance (LOD score 3.9) that contributes to CD susceptibility in families with early-
onset disease. Both of these genomic regions contain numerous genes that are important to the immune and
inﬂammatory systems and that provide good targets for future candidate-gene studies.
Introduction
Crohn disease (CD) and ulcerative colitis (UC) are in-
ﬂammatory bowel diseases (IBDs) associated with dis-
tinct clinical and pathological proﬁles. Speciﬁcally, CD
is characterized by discontinuous, transmural inﬂam-
mation potentially involving any part of the gastro-
intestinal tract, whereas in UC the inﬂammatory process
is continuous and restricted to the mucosa of the large
intestine.
Although both CD andUC are associatedwith altered
expression of both proinﬂammatory and immuno-
regulatory cytokines within the intestinal mucosa, the
patterns of cytokine alteration differ between the two
conditions. Despite these and other differences, cumu-
lative data garnered from epidemiological studies of
these IBDs have revealed that relatives of individuals
with either CD or UC are at increased risk for devel-
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oping either form of IBD. Moreover, a number of IBD-
affected individuals appear to manifest an overlap syn-
drome, known as “indeterminate colitis” (IC), which is
characterized by features of both CD and UC. These
observations suggest that at least some susceptibility
genes will be shared by UC and CD.
The search for IBD-susceptibility genes has resulted
in the identiﬁcation of several loci with potential rele-
vance to IBD etiology. These include IBD1 (MIM
266600), a putative CD-susceptibility locus that maps
to the pericentromeric region of chromosome 16 (Hugot
et al. 1996), and IBD2 (MIM 602458), mapped to a
41-cM region, on chromosome 12, surrounding the
D12S83 marker and implicated in both CD and UC
(Satsangi et al. 1996). The sibling relative risks (ls) for
IBD1 and IBD2 are relatively low, having been esti-
mated at 1.3 and 2.0, respectively. These localizations
have been replicated in some but not all follow-up stud-
ies (Ohmen et al. 1996; Brant et al. 1998; Cavanaugh
et al. 1998; Cho et al. 1998; Duerr et al. 1998; Rioux
et al. 1998a; Annese et al. 1999; Hampe et al. 1999a)
and, on the basis of available data, together would ac-
count for only a fraction of the heritability of IBD.
Subsequent genomewide searches for susceptibility loci
have also provided some suggestive evidence for linkage
to other regions of the genome (Cho et al. 1998; Hampe
et al. 1999a; Ma et al. 1999). The differences observed
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between the results of the various genomewide screens
and follow-up linkage studies may be related to the
difﬁculties in the detection of genes of modest effects in
complex traits (Risch and Merikangas 1996) and to
genetic heterogeneity. Speciﬁcally, this could be ex-
plained by a small number of alleles conferring modest
susceptibility to IBD that are segregating at different
frequencies in the given populations.
Considering (a) that not all IBD-susceptibility loci
have been identiﬁed to date and (b) the possibility that
they might be more easily identiﬁed in a population
different from those previously studied, we decided to
undertake a genomewide search for susceptibility loci
in a Canadian population with IBD. This search began
with identiﬁcation of families in the Toronto region that
had multiple siblings affected by IBD. Subsequently we
examined the segregation of 312 microsatellite markers
in 183 affected sibling pairs (ASPs) and in all available
parents, using multipoint sib-pair analysis. This ap-
proach identiﬁed two novel loci of genomewide signif-
icance, in chromosomal regions 19p13 and 5q31-q33,
and provided evidence that these loci confer suscepti-
bility to IBD and CD, respectively, in this Canadian
population. Both loci appear to have higher ls values
in this population, compared with that in the previously
reported loci IBD1 and IBD2. Furthermore, both of
these genomic regions contain many genes that are im-
portant to immune function and regulation and, given
the inﬂammatory nature of these diseases, that represent
interesting candidate genes.
Families and Methods
Families
Multicase families with two or more siblings affected
by IBD were identiﬁed by review of clinical charts of all
patients registered in the Mount Sinai Hospital Inﬂam-
matory Bowel Disease Centre database (McLeod et al.
1997) and The Hospital for Sick Children IBD database.
Patients also were referred by physicians in the greater
Toronto area. To conﬁrm and update information ob-
tained from these records, all patients were sent a ques-
tionnaire inquiring about the presence of a family history
of IBD. Individuals identiﬁed as having one or more IBD-
affected ﬁrst-degree relatives were invited to participate
and were asked for permission to contact other affected
and unaffected family members. Endoscopic, histologi-
cal, and radiological, reports, as well as clinical data,
were obtained on all affected individuals, and these re-
ports were reviewed by at least one of the authors of
this study, for diagnosis veriﬁcation based on standard
criteria. Venous blood sampling was performed on af-
fected individuals and their parents, and DNA was ex-
tracted by a salting-out procedure. Inclusion of families
within the Jewish-ethnicity subgroup required a mini-
mum of three grandparents of Jewish origin. Ethics ap-
proval for this study was given by the University of To-
ronto Ethics Committee. Written informed consent was
obtained from all participants.
Genotyping
Genomic DNA was extracted from peripheral blood
lymphocytes from probands and family members of 158
White pedigrees. All parental DNA samples were ge-
notyped when available: 140 families had both parents
available, 17 families had one parent available, and 1
family had neither parent available. The genomewide
scan, with an average intermarker spacing of 12 cM,
was performed by use of a modiﬁed version of the Co-
operative Human Linkage Centre Screening Set, version
6.0, that also included Ge´ne´thon markers. These 312
loci were ampliﬁed with ﬂuorescently labeled primers
(Research Genetics), in separate PCRs, and the products
were then multiplexed into panels by being pooled be-
fore electrophoresis on ABI 377 sequencers (PE Bio-
systems). Fluorescent genotyping gels were analyzed
in an automated system developed at the Whitehead
Institute/MIT Center for Genome Research (GENE-
HUNTER 2.0, Whitehead Institute for Biomedical
Research/MIT Center for Genome Research). Further
details of the genotyping system have been described
elsewhere (Rioux et al. 1998b).
Both the region of suggestive linkage on chromosome
5 and the surrounding regions of poor information con-
tent were further investigated with additional microsat-
ellite markers. Speciﬁcally, 34 markers were genotyped
betweenmarkers D5S1470 andD5S1471, decreasing the
average spacing between markers to ∼3 cM in this 125-
cM region. This higher-density mapping was performed
on the original samples and on an additional 13 families
(12 “CD only” families and 1 “mixed” family), for a
total of 171 pedigrees analyzed. These additional fam-
ilies consisted of 15 ASPs where both members had CD
and one mixed ASP where one sibling had CD and the
other had UC.
Statistical Analysis
Multipoint sib-pair analysis of the data from the ge-
nomewide scan and from the higher-density mapping on
chromosome 5 was performed by the MAPMAKER/
SIBS functions implemented in GENEHUNTER 2.0
(Daly et al. 1998). All sib pairs from sibships with more
than two affected individuals were counted but were
conservatively down-weighted by a factor of 2/n, where
n is the number of affected individuals in the family
(Suarez and Hodge 1979). Linkage analysis of different
phenotypic subgroups was performed on the two chro-
mosomes with the greatest evidence for linkage (i.e.,
chromosomes 5 and 19). Speciﬁcally multipoint sib-pair
analysis was performed by use of four different phe-
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Table 1
Summary of Families and ASPs Included in the Genomewide Screen
PEDIGREE TYPE
NO. OF
FAMILIES
NO. OF ASPS
Both Sibs with CD Both Sibs with UC
One Sib with CD
and One Sib with UC
One Sib with IC
and One Sib with
Either UC or CD Total
CD only 104 116 ) ) ) 116
UC only 20 ) 20 ) ) 20
Mixed 34 8 ) 26 13 47
Total 158 124 20 26 13 183
notypic categories: IBD, UC, CD, and CD16. In the ﬁrst,
all individuals with CD, UC, or IC were designated as
affected; in the second, only individuals with UC were
designated as affected; in the third, only individuals with
CD were designated as affected; and, in the fourth, only
individuals with CD were designated as affected and
only families with at least one affected sibling diagnosed
at age16 years were included. Exclusion mapping was
also performed with the GENEHUNTER 2.0 package;
exclusion was declared at a LOD score of 2.
To establish appropriate thresholds for suggestive and
signiﬁcant genomewide linkage for these particular data
sets, simulations were performed by generation of arti-
ﬁcial genotype data with identical family structures
(GENSIM computer program designed by Mark J. Daly
[unpublished data]). These simulations matched our
data sets with respect to marker density, marker inform-
ativeness, individuals genotyped, affected status, and
fraction of missing data. Speciﬁcally, 500 whole-genome
screens were generated at the genome-scan marker den-
sity (1 marker every 10 cM, throughout). In this fashion,
the genomewide thresholds for suggestive and signiﬁcant
linkage were determined to be LOD scores of 1.9 and
3.3, respectively. Since we tested only one pheno-
type—that is, the all-inclusive “IBD”—no correction for
multiple testing was necessary. Subsequent to the higher-
density mapping of the 5q31-q33 region, we simulated
1,000 whole-genome screens at the higher marker den-
sity (1 marker every 2 cM, throughout), to assess the
signiﬁcance of the linkage results. Only 8 simulated ge-
nome scans of 1,000 ( ) had values that exceededP ! .01
our observed value of 3.94 on chromosome 5. Correc-
tion for multiple testing was necessary, since we exam-
ined the suggestive regions for different hypotheses: we
examined ﬁve different subgroups based on phenotype,
age at diagnosis, and ethnicity and performed limited
correlation tests. Speciﬁcally, to search for interactions
either between the two novel loci described herein or
between these loci and IBD1 and IBD2, we examined
the correlation between family-based multipoint sib-pair
linkage scores computed by GENEHUNTER 2.0, as de-
scribed elsewhere (Cox et al. 1999). These analyses (sub-
group analysis and correlation tests) should not be con-
sidered as whole-genome scan tests, because they were
done only on regions of suggestive linkage. Even if all
ﬁve tests were to be considered independent, our result
is still likely to be seen in less than .05 genomewide
scans—the accepted threshold for declaration that link-
age is signiﬁcant.
To examine the possibility of obvious segregation dis-
tortion affecting our linkage results on either chromo-
somes 5 or chromosome 19, we used the transmission/
disequilibrium test (Spielman and Ewens 1996).
Speciﬁcally, a single trio was selected at random from
each family, and the alleles at each marker were ex-
amined for excess transmission. No single marker or pair
of markers had any demonstrable transmission-ratio
distortion.
The analysis of the subgroup of families with early-
onset cases (i.e., families that would be expected to have
greater disease severity and familial component) was
done by selection of families in which the youngest age
at diagnosis was16 years. This cutoff value was chosen
after observation that the distribution of the youngest
age at diagnosis in a family was much better ﬁt by two
Gaussian distributions, with means at 13.1 and 20.2,
than by a single Gaussian distribution ( , 3 df;2x = 19.8
). The Gaussian ﬁtting was done by an imple-P ! .0002
mentation of the Levenberg-Marquardt method, as de-
scribed elsewhere (Press et al. 1992).
Results
To further deﬁne the genetic basis of IBD, we performed
a genomewide scan on 158 families comprising 183
ASPs with IBD (table 1). These families included 116
ASPs with CD, 20 ASPs with UC, and 47 mixed ASPs
(i.e., CD, UC, and/or IC). In the majority of families,
parental-DNA samples were available for genotyping:
88.6%, 10.8%, and 0.6% had DNA from both parents,
one parent, or neither parent, respectively. All ASPs and
available parents were genotypedwith 312microsatellite
markers covering the genome at an average spacing of
12 cM.
Multipoint sib-pair analysis of the data was then per-
formed; the results are shown in ﬁgure 1. On the basis
of simulation experiments, the genomewide threshold
for suggestive linkage (i.e., the score expected to occur
Figure 1 Multipoint sib-pair analysis results for the IBD genome scan. Multipoint LOD scores were calculated by use of the MAPMAKER/SIBS functions implemented in GENEHUNTER 2.0.
The vertical axis indicates the LOD score along the length of each chromosome, and the tick marks indicate the positions of the microsatellite markers. The two horizontal lines indicate the published
genomewide thresholds (Lander and Kruglyak 1995) for suggestive (LOD score 2.2) and signiﬁcant linkage (LOD score 3.6). The horizontal bars on chromosomes 12 and 16 indicate the position
of the previously reported IBD-susceptibility loci IBD1 and IBD2 (Hugot et al. 1996; Satsangi et al. 1996).
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Table 3
Summary of Signiﬁcant Linkage Results,
according to Phenotypic Category
Chromosome and
Phenotypic Category
No. of
Pedigrees
Peak LOD
Score
5:
IBD 171 2.4
UC 24 0.1
CD 122 3.0
CD16 50 3.9
19:
IBD 158 4.6
UC 24 2.9
CD 110 3.0
CD16 46 1.5
Table 2
Summary of Genome-Scan Results
Chromosomal
Region Interval of Peak Linkage
Peak LOD
Score
3p D3S1766–D3S1285 2.4
5q31-33 D5S816–D5S1480 3.0
6p D6S1281–D6S1019 2.3
19p13 D19S591/D5S247–GATA21G05 4.6
one time at random in a genomewide scan) was deter-
mined to be a LOD score of 1.9. Speciﬁcally, 500 whole-
genome screens were generated to simulate the actual
pedigrees and genotype information. This calculated
threshold was quite similar to the recommended thresh-
old, estimated in the limit of an inﬁnitely dense genetic
map, of a LOD score of 2.2 (Lander and Kruglyak
1995). When either of these values was used, four
regions in our genomewide search surpassed the thresh-
old for suggestive linkage to IBD. As shown in ﬁgure 1
and table 2, these loci localized to chromosomal regions
19p13, 5q31-33, 3p, and 6p, with peak LOD scores of
4.6, 3.0, 2.4, and 2.3, respectively. Moreover, the evi-
dence for linkage at the chromosome 19 locus was
greater than a LOD score of 3.6, the threshold for ge-
nomewide signiﬁcance (Lander and Kruglyak 1995). In
addition, signiﬁcant marker-allele sharing between sib-
lings was observed at this 19p13 locus (proportion of
sibs sharing 0, 1, and 2 alleles: , , andZ = .08 Z = .500 1
, respectively). The region on chromosomeZ = .422
19p13 thus appears to represent a novel IBD-suscepti-
bility locus, with an apparent ls of 2.2 (95% conﬁdence
interval 1.6–2.8).
Among the chromosomal loci showing suggestive
linkage to IBD, the 5q31-q33 region was of particular
interest, because the region spans the major immuno-
regulatory cytokine-gene cluster. Accordingly, we gen-
otyped the families in the initial scan, together with 13
newly ascertained families, for 34 additional microsat-
ellite markers in and around this region. Multipoint sib-
pair analysis was then performed on the data, with the
families being stratiﬁed by clinical phenotype (i.e., CD
vs. UC). Although, with the additional markers and
families (table 3), there was a decrease in the linkage
score for the all-inclusive IBD phenotypic category,
analysis of the UC and CD categories clearly demon-
strated that linkage to this locus was almost exclusively
found in the CD families.
Furthermore, previous studies of CD have revealed
that early age at onset is associated with increased dis-
ease severity and increased heritability (Polito et al.
1996). Accordingly, the chromosome 5 linkage data
were examined to speciﬁcally assess the subgroup of
CD16 families. As shown in table 3, the 50 families in
this subgroup had a substantially higher peak LOD
score: 3.9. This peak, centered around marker
D5S2497, showed 70% sharing between affected sib-
lings ( , , and ), and an apparentZ = .05 Z = .50 Z = .450 1 2
ls of 2.8 (95% conﬁdence interval 1.7–4.7). On the
basis of simulation experiments at this higher marker
density, the genomewide threshold for signiﬁcant link-
age (i.e., the score expected to occur .05 times in a
genome scan) was determined to be a LOD score of 3.3.
Our observed LOD score therefore exceeds this thresh-
old, as well as the signiﬁcance threshold based on an
inﬁnitely dense map (Lander and Kruglyak 1995), and
thus reveals that the chromosomal region 5q31-33 con-
tains a locus for susceptibility to early-onset CD. By
contrast, the evidence for linkage on chromosome
19p13 was not enhanced by an identical age–based
stratiﬁcation of families (table 3).
In view of both the increased frequency of IBD and
increased familial risk for these diseases within the Jew-
ish population (Yang et al. 1993), the linkage data were
also analyzed by stratiﬁcation of the families as Jewish
or non-Jewish. As indicated in table 4, the results of
this analysis revealed that the evidence for linkage in
the chromosome 5q31-33 and 19p13 regions was com-
mon to both the Jewish and non-Jewish families. In
addition, since previous reports have raised the possi-
bility of epistatic interactions between IBD-susceptibil-
ity loci (Cho et al. 1998), we searched for evidence of
interlocus interactions, by evaluating correlations be-
tween within-family linkage scores. No signiﬁcant pos-
itive or negative correlations, either between the novel
loci on chromosomes 5 and 19 or between either the
loci reported herein and the IBD1 and IBD2 loci re-
ported elsewhere (data not shown), were detected.
It should be noted that the other two suggestive loci,
although showing weaker evidence of linkage to IBD,
are located near previously reported loci of suggestive
linkage. Speciﬁcally, the chromosome 3p linkage peak
in the present study is located ∼10 cM from a locus
seen in a U.K. population (Satsangi et al. 1996), and
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Table 4
Contribution of Ethnic Subgroups to Signiﬁcant
Linkage Results
Chromosome and
Phenotypic Category
No. of
Pedigrees
Peak LOD
Score
5:
CD16, Jewish 24 2.2
CD16, non-Jewish 26 2.1
19:
IBD, Jewish 44 2.2
IBD, non-Jewish 114 2.7
the chromosome 6p linkage peak in the present study
is located ∼15 cM from a locus seen in a western-
European population (Hampe et al. 1999b).
Finally, to assess whether the IBD1 and IBD2 loci
are contributing to the IBD susceptibility in the popu-
lation that we studied, we performed exclusion map-
ping. These analyses demonstrate that we can exclude
almost all of chromosome 12, for loci of even modest
effects (i.e., ), but that, because of excess shar-l 1 2.0s
ing—that is, 55% ( , , and )—inZ = .23 Z = .45 Z = .320 1 2
the IBD1 region, we can exclude, on chromosome 16,
only loci conferring , suggesting that IBD1 (re-l 1 4s
ported ) could be playing a role in this Canadianl ∼ 1.3s
population with IBD.
Discussion
Disease susceptibility in IBD is complex and most cer-
tainly involves the interaction between environmental
factors and multiple genes. Although our knowledge of
the former remains limited, a number of genomewide
linkage studies have begun to increase our knowledge
of the latter. Indeed, the ﬁrst two completed studies
revealed signiﬁcant susceptibility loci, now known as
“IBD1” and “IBD2,” on chromosomes 16 and 12, re-
spectively (Hugot et al. 1996; Satsangi et al. 1996); these
loci were reported to contain genes that contributed to
the susceptibility to CD and IBD, respectively, albeit of
modest effect ( ). Not all subsequent studies werel  2s
conﬁrmatory, and some provided evidence for additional
susceptibility loci (Hampe et al. 1999a; Ma et al. 1999;
Cho et al. 1998; Rioux et al. 1998a). Considering that
the overall ls values for CD and UC are relatively large
(35 and 15, respectively) and that the reported loci could
not explain the entire genetic susceptibility, we decided
to examine a Canadian population with IBD.
The results of this genomewide search of 183 Ca-
nadian ASPs revealed the presence of a novel locus, on
chromosomal region 19p13, that confers susceptibility
to IBD. These results also provided evidence for three
loci suggestive of linkage that are located on 5q31-q33,
3p, and 6p. The 5q31-q33 region was further studied,
with additional genetic markers, and stratiﬁcation of
the data set according to clinical phenotype demon-
strated that the linkage evidence was almost exclusively
within the CD subset. In an attempt to further under-
stand the contribution of this suggestive locus to CD
susceptibility, we examined the 50 families with early-
onset disease, since this has been suggested as an ap-
proach to deﬁnition of a subgroup of patients with in-
creased relative risk (Lander and Schork 1994). This
approach was used successfully in determination of the
linkage to breast cancer (Hall et al. 1992) and is sup-
ported by previous studies of CD, which indicated that
early onset of disease was associated with increased dis-
ease severity and increased heritability (Polito et al.
1996). Indeed, the present analysis revealed a 5q31-q33
locus, of genomewide signiﬁcance, that contributes to
CD susceptibility primarily in families with early-onset
cases. It is noteworthy that, although none of the ﬁve
previously reported genomewide studies have provided
evidence for linkage to the 19p13 locus, the studies by
Cho et al. (1998) and Ma et al. (1999) have shown
some evidence for linkage to the 5q31-q33 region, with
LOD scores of 1.2 and 2.2, respectively.
The identiﬁcation of 5q31-33 and 19p13 as potential
locations for IBD-susceptibility genes is of particular
interest in view of the biology of the genes known to
map within these regions. The chromosomal segment
corresponding to 5q31-33 includes many cytokine
genes, including those encoding interleukins 3–5 and
13, as well as colony-stimulating factor 2. Although the
etiology of IBD remains unknown, a role for immu-
nological dysregulation is widely supported by the
results of numerous studies on the immune-cell popu-
lations and on cytokine expression patterns within
IBD-affected intestinal tissue (Kmiec 1998). In fact, a
clustering of loci on the syntenic region in mice, for
numerous models of autoimmunity, has suggested that
genes in this region are implicated in the Th1/Th2 bal-
ance (Vyse and Todd 1996); the perturbation of which
may also be important in development of IBD. This is
further supported by recent linkage data derived from
a murine model of colitis, which has localized an IBD-
susceptibility gene to this same syntenic region on
mouse chromosome 11 (Mahler et al. 1999).
As does the 5q31-33 region, the chromosome
19p13 region also contains a number of genes rep-
resenting strong candidates for IBD; these include the
genes encoding intercellular adhesion molecule 1
(ICAM1), complement component 3 (C3), the throm-
boxane A2 receptor (TBXA2), leukotriene B4 hy-
droxylase (LTB4H), and the janus protein tyrosine
kinases TYK2 and JAK3. The relevance of any of
these genes to IBD etiology remains to be elucidated,
but at least some of the genes already have been im-
plicated in IBD pathogenesis. For example, modest
associations have been reported between selected
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ICAM1 and C3 polymorphisms and IBD (Elmgreen
et al. 1984; Yang et al. 1995); and interference with
the TBXA2-mediated (Takao et al. 1997) and
LTB4H-mediated (Hawkey et al. 1992) inﬂammatory
pathways has been shown to be of potential thera-
peutic value in experimental IBD models. The janus
kinases also represent logical candidates for involve-
ment in IBD, in view of their critical roles in the
coupling of cytokine stimulation to cell activation
(Onishi et al. 1998).
Higher-density mapping will be necessary to follow
up the suggestive linkages to chromosomes 3 and 6 loci
identiﬁed here, but it is interesting to note that the link-
age peaks reported herein are located near previously
reported suggestive loci. In particular, the linkage peak
on chromosome 6 lies ∼15 cM proximal to the major
histocompatibility complex (MHC) class II region, a
region widely recognized as playing an integral role in
predisposition to immunological disease. Importantly, a
recent study has described linkage to this chromosome
6 region (Hampe et al. 1999b), and a large metanalysis
of the results derived from 29 different studies also has
reported both CD and UC to be associated with speciﬁc
class II alleles (Stokkers et al. 1999). It remains to be
determined, however, whether the susceptibility is ac-
tually conferred by an MHC gene or by a gene in dis-
equilibrium with this complex.
In conclusion, this study reports two novel suscep-
tibility loci: a locus on chromosome 5q31-33, which
appears to confer particular susceptibility to a subset of
early-onset CD-affected individuals; and a locus on
chromosome 19p13, which confers susceptibility to
both CD and UC. Both loci appear to have higher ls
values in this population, compared with the previously
reported loci IBD1 and IBD2. Further work will be
necessary to elucidate the causative genes and the mech-
anisms by which they contribute to the genetic suscep-
tibility to IBD.
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